136137-86-5

Basic information

• Product Name: 2,5-Pyrrolidinedione, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(phenylmethyl)-, (3R,4R)-
• CAS NO: 136137-86-5
• Molecular Formula: C23H39NO4Si2
• Molecular Weight: 449.738
• Mol File: 136137-86-5.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 2,5-Pyrrolidinedione, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(phenylmethyl)-, (3R,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Pyrrolidinedione, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(phenylmethyl)-, (3R,4R)-(136137-86-5)
• EPA Substance Registry System: 2,5-Pyrrolidinedione, 3,4-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(phenylmethyl)-, (3R,4R)-(136137-86-5)

Safety Data

• Hazardous Substances Data: 136137-86-5(Hazardous Substances Data)

Usage

Structure

Chiral compound with two stereocenters

Usage

Organic Synthesis: Versatile intermediate, especially in pharmaceutical industry
Pharmaceuticals: Potential applications in drug production and synthesis of biologically active molecules
Material Sciences: Possible uses in material sciences
Catalysis: Potential application as a catalyst

Upstream product

• 100-46-9 benzylamine 
• 75172-31-5 (3R,4R)-1-benzyl-3,4-dihydroxypyrrolidine-2,5-dione 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 87-69-4 L-Tartaric acid 
• 136137-85-4 (3R,4R)-1-benzyl-2,5-dioxopyrrolidine-3,4-diyl diacetate 

Downstream Products

• 162466-21-9 (2S,3S,4S)-1-Benzyl-2-methyl-pyrrolidine-3,4-diol 
• 502841-31-8 (2S,3S,4S)-1-Benzyl-2-isopropyl-pyrrolidine-3,4-diol 
• 502841-32-9 (2S,3S,4S)-1-Benzyl-2-phenyl-pyrrolidine-3,4-diol 
• 502841-30-7 (2S,3S,4S)-1,2-Dibenzyl-pyrrolidine-3,4-diol 
• 502841-26-1 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-methyl-pyrrolidine 
• 502841-28-3 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-isopropyl-pyrrolidine 
• 502841-22-7 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-methyl-pyrrolidin-2-one 
• 502841-24-9 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-isopropyl-pyrrolidin-2-one 
• 502841-29-4 (2S,3S,4S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-2-phenyl-pyrrolidine 
• 502841-25-0 (3R,4S,5S)-1-Benzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-5-phenyl-pyrrolidin-2-one 
• 502841-27-2 (2S,3S,4S)-1,2-Dibenzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine 
• 502841-23-8 (3R,4S,5S)-1,5-Dibenzyl-3,4-bis-(tert-butyl-dimethyl-silanyloxy)-pyrrolidin-2-one 
• 138228-45-2 (3S,4S)-1-benzyl-3,4-bis{[(tert-butyl)dimethylsilyl]oxy}pyrrolidine 
• 138228-47-4 (3S,4S)-3,4-bis<(tert-butyl)dimethylsilyloxy>pyrrolidine 

Relevant articles and documents

Unexpected rearrangements of rhodium carbenoids containing a pyrrolidin-1-yl group

Ketone- and ester-substituted diazo compounds, which contain a pyrrolidine moiety were treated with dirhodium tetraacetate generating the corresponding rhodium carbenoids. They were expected to insert into a CH bond of the pyrrolidine moiety but reacted differently. The ketone-substituted rhodium carbenoid underwent a Wolff rearrangement. The resulting ketene continued to react by lactamization and electrocyclic ring-opening and gave an acrylamide. The ester-substituted rhodium carbenoid underwent a [1.2]-shift of the (pyrrolidin-1-yl)methyl moiety, which resulted in a methacrylic ester. For each rearrangement a mechanism is suggested.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.